Related Experiment Video
Updated: Mar 1, 2026
08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.9K
Changes in Kidney Function in a Population With Essential Hypertension in Real Life Settings
Anastasia G Ptinopoulou1, Maria I Pikilidou, Ioannis M Tziolas
1Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, UK. anastasiap@gmx.com.
Iranian Journal of Kidney Diseases
|June 3, 2017
Summary
Certain antihypertensive drugs like diuretics, RASI, CCBs, and beta-blockers protect kidneys. Combining renin-angiotensin-system inhibitors (RASI) with calcium channel blockers (CCBs) did not improve kidney function but lowered blood pressure.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Hypertension is a major risk factor for chronic kidney disease (CKD) progression.
- Numerous antihypertensive drugs exist, with their effects on kidney function extensively studied in randomized controlled trials.
- Observational studies offer insights into real-world clinical practice and longitudinal kidney function changes.
Purpose of the Study:
- To investigate the impact of different antihypertensive drug categories and their combinations on kidney function over time in hypertensive patients.
- To evaluate the renoprotective effects of specific drug classes and their interactions, particularly involving renin-angiotensin-system inhibitors (RASI) and calcium channel blockers (CCBs).
Main Methods:
- Mixed model repeated measures analysis was used.
- Data from 779 essential hypertension patients in a Greek outpatient clinic were analyzed.
- Antihypertensive drugs were categorized, and their effects and combinations (with/without RASI, RASI with CCBs) were evaluated.
Main Results:
- Diuretics, RASI, CCBs, and beta-blockers demonstrated significant renoprotective and blood pressure-lowering effects.
- Combinations involving RASI showed a lesser beneficial impact on kidney function compared to CCBs alone.
- Combining RASI with CCBs did not yield additional kidney function benefits but did enhance systolic blood pressure reduction.
Conclusions:
- RASI exhibit a significant, though comparatively smaller, renoprotective effect.
- No additional kidney function benefits were observed when combining RASI with CCBs, despite a greater blood pressure-lowering effect.
More Related Videos
Related Concept Videos
01:18Hypertension and Regulation of Blood Pressure
4.6K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.6K
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
685
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
685
01:28Chronic Kidney Disease III: Interprofessional Care
529
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
529
01:25Chronic Kidney Disease I: Introduction
863
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
863
01:28Hypertension I: Introduction
1.1K
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
1.1K
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
284
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
284